Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder



Status:Archived
Conditions:Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2009
End Date:August 2011

Use our guide to learn which trials are right for you!

A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder


The primary purpose of this study is to compare the long-term efficacy and safety of
desvenlafaxine succinate sustained release versus placebo in adults with Major Depressive
Disorder, using a randomized withdrawal design. Randomized withdrawal means that after
receiving desvenlafaxine succinate sustained release for a predetermined period of time,
subjects will be selected by chance to either continue receiving the study drug or to be
withdrawn from the study drug and receive placebo for the remainder of their participation
in the trial. Subjects will not know to which group they have been assigned.

The study consists of an up to 14-day screening period followed by an 8-week open-label
period in which subjects will knowingly receive 50 mg/day of desvenlafaxine succinate
sustained release. Subjects who do not respond to treatment, demonstrating no significant
change in their depressive symptoms, will be withdrawn from participation at the end of this
period. Responding subjects will receive an additional 3 months of open-label desvenlafaxine
succinate sustained release at the same dose. Subjects with stable response to treatment at
the conclusion of this 3 month period will be randomized to either desvenlafaxine succinate
sustained release at 50 mg/day or placebo in a blinded manner for an additional 6 months or
until symptoms of depression return. Following discontinuation at any point after enrollment
in the study, subjects will receive two weeks of follow-up monitoring, including one week of
blinded taper with 25 mg/day of desvenlafaxine succinate sustained release treatment for any
subjects who have been taking desvenlafaxine succinate sustained release prior to
discontinuation. Subjects assigned to placebo will receive a blinded placebo taper.
Following taper, subjects will be evaluated for one additional week to monitor safety.



We found this trial at
11
sites
Akron, Ohio 44314
?
mi
from
Akron, OH
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials
Arvada, Colorado 80005
?
mi
from
Arvada, CO
Click here to add this to my saved trials
Ashland, Oregon 97520
?
mi
from
Ashland, OR
Click here to add this to my saved trials
Atlanta, Georgia 30309
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baltimore, Maryland 21234
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Beckley, West Virginia 25801
?
mi
from
Beckley, WV
Click here to add this to my saved trials
Bloomingdale, Illinois 60108
?
mi
from
Bloomingdale, IL
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90027
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Seattle, Washington 98166
?
mi
from
Seattle, WA
Click here to add this to my saved trials